Anjli Kukreja

3.1k total citations · 1 hit paper
25 papers, 2.5k citations indexed

About

Anjli Kukreja is a scholar working on Immunology, Genetics and Hematology. According to data from OpenAlex, Anjli Kukreja has authored 25 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 8 papers in Genetics and 4 papers in Hematology. Recurrent topics in Anjli Kukreja's work include Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (11 papers) and Diabetes and associated disorders (8 papers). Anjli Kukreja is often cited by papers focused on Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (11 papers) and Diabetes and associated disorders (8 papers). Anjli Kukreja collaborates with scholars based in United States, India and Switzerland. Anjli Kukreja's co-authors include Noel K. Maclaren, John Marker, Karen Lin‐Su, Chenhui Zhang, Zhongsheng Sun, Svetlana Ten, Maureen M. Sanz, Steven A. Porcelli, Mark A. Exley and Brian Wilson and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Blood.

In The Last Decade

Anjli Kukreja

24 papers receiving 2.4k citations

Hit Papers

Multiple immuno-regulatory defects in type-1 diabetes 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multiple immuno-regulatory defects in type-1 diabetes
    2002 547 citations Anjli Kukreja, John Marker et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anjli Kukreja United States 17 1.8k 701 511 363 344 25 2.5k
Arno R. van der Slik Netherlands 26 1.3k 0.7× 547 0.8× 248 0.5× 239 0.7× 71 0.2× 47 2.0k
Jonathan H. Esensten United States 16 1.4k 0.8× 326 0.5× 678 1.3× 437 1.2× 76 0.2× 21 2.3k
Mauro Congia Italy 25 1.0k 0.6× 1.1k 1.5× 138 0.3× 447 1.2× 226 0.7× 50 2.7k
J. S. Lanchbury United Kingdom 18 637 0.4× 345 0.5× 647 1.3× 723 2.0× 174 0.5× 41 2.4k
J A Hansen United States 23 1.4k 0.8× 217 0.3× 385 0.8× 404 1.1× 479 1.4× 35 2.3k
Mari Malkki United States 31 2.1k 1.2× 202 0.3× 412 0.8× 481 1.3× 1.8k 5.3× 80 3.3k
Gisela Orozco United Kingdom 31 1.3k 0.7× 624 0.9× 264 0.5× 764 2.1× 248 0.7× 75 2.6k
Yojiro Arinobu Japan 26 1.5k 0.8× 193 0.3× 281 0.5× 781 2.2× 516 1.5× 77 2.8k
Tie Zheng Hou United Kingdom 17 1.7k 0.9× 258 0.4× 863 1.7× 256 0.7× 67 0.2× 20 2.3k
Eric T. Elwood United States 16 1.8k 1.0× 315 0.4× 222 0.4× 320 0.9× 197 0.6× 37 3.1k

Countries citing papers authored by Anjli Kukreja

Since Specialization
Citations

This map shows the geographic impact of Anjli Kukreja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjli Kukreja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjli Kukreja more than expected).

Fields of papers citing papers by Anjli Kukreja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjli Kukreja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjli Kukreja. The network helps show where Anjli Kukreja may publish in the future.

Co-authorship network of co-authors of Anjli Kukreja

This figure shows the co-authorship network connecting the top 25 collaborators of Anjli Kukreja. A scholar is included among the top collaborators of Anjli Kukreja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjli Kukreja. Anjli Kukreja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kukreja, Anjli, Melissa A. Lasaro, Jianping Tang, et al.. (2019). Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1. Nucleic Acid Therapeutics. 29(2). 104–113. 15 indexed citations
2.
Mahadevan, Daruka, Mark C. Lanasa, Charles M. Farber, et al.. (2019). Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. Journal for ImmunoTherapy of Cancer. 7(1). 227–227. 63 indexed citations
3.
Cofiell, Roxanne, Anjli Kukreja, Yan Yan, et al.. (2015). Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 125(21). 3253–3262. 143 indexed citations
4.
Cofiell, Roxanne, Anjli Kukreja, Yan Yan, et al.. (2013). Biomarkers Of Complement and Endothelial Activation, Inflammation, Thrombosis and Renal Injury In Patients (pts) With aHUS Treated With Eculizumab (ECU). Blood. 122(21). 2184–2184. 2 indexed citations
5.
6.
Dhodapkar, Kavita M., Devi Banerjee, John E. Connolly, et al.. (2007). Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. The Journal of Experimental Medicine. 204(6). 1359–1369. 115 indexed citations
7.
Špíšek, Radek, Anjli Kukreja, Lin-Chi Chen, et al.. (2007). Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy. The Journal of Experimental Medicine. 204(4). 831–840. 152 indexed citations
8.
Dhodapkar, Kavita M., Devi Banerjee, John F. Connolly, et al.. (2007). Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. The Journal of Experimental Medicine. 204(10). 2489–2489. 1 indexed citations
9.
Kukreja, Anjli, Kavita M. Dhodapkar, Amitabha Mazumder, et al.. (2006). Enhancement of clonogenicity of human multiple myeloma by dendritic cells. The Journal of Experimental Medicine. 203(8). 1859–1865. 103 indexed citations
10.
Kukreja, Anjli, Amitabha Mazumder, David H. Vesole, et al.. (2006). Bortezomib disrupts tumour–dendritic cell interactions in myeloma and lymphoma: therapeutic implications. British Journal of Haematology. 136(1). 106–110. 28 indexed citations
11.
Chang, D., Keren Osman, John E. Connolly, et al.. (2005). Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. The Journal of Experimental Medicine. 201(9). 1503–1517. 337 indexed citations
12.
Kukreja, Anjli, John Marker, Chenhui Zhang, et al.. (2002). Multiple immuno-regulatory defects in type-1 diabetes. Journal of Clinical Investigation. 109(1). 131–140. 28 indexed citations
13.
Kukreja, Anjli, John Marker, Chenhui Zhang, et al.. (2002). Multiple immuno-regulatory defects in type-1 diabetes. Journal of Clinical Investigation. 109(1). 131–140. 497 indexed citations
14.
Kukreja, Anjli, John Marker, Chenhui Zhang, et al.. (2002). Multiple immuno-regulatory defects in type-1 diabetes. Journal of Clinical Investigation. 109(1). 131–140. 547 indexed citations breakdown →
15.
Kukreja, Anjli, et al.. (2002). NKT Cell Defects in NOD Mice Suggest Therapeutic Opportunities. Journal of Autoimmunity. 19(3). 117–128. 16 indexed citations
16.
Kukreja, Anjli & Noel K. Maclaren. (2002). NKT Cells and Type-1 Diabetes and the "Hygiene Hypothesis" to Explain the Rising Incidence Rates. Diabetes Technology & Therapeutics. 4(3). 323–333. 27 indexed citations
17.
Goswami, Ravinder, N Kochupillai, Nandita Gupta, et al.. (2001). Islet cell autoimmunity in youth onset diabetes mellitus in Northern India. Diabetes Research and Clinical Practice. 53(1). 47–54. 25 indexed citations
18.
Lin‐Su, Karen, Anjli Kukreja, & Noel K. Maclaren. (2001). Diabetes Vaccines: A Future to be Realized. Diabetes Technology & Therapeutics. 3(3). 451–461. 5 indexed citations
19.
Chen, Qiao-Yi, Anjli Kukreja, Frank Svec, et al.. (2000). The Human Leukocyte Antigen HLA DRB3∗0202/DQA1∗0501 Haplotype Is Associated with Graves’ Disease in African Americans. The Journal of Clinical Endocrinology & Metabolism. 85(4). 1545–1549. 44 indexed citations
20.
Kukreja, Anjli & Noel K. Maclaren. (1999). Autoimmunity and Diabetes. The Journal of Clinical Endocrinology & Metabolism. 84(12). 4371–4378. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arno R. van der Slik Breakdown of academic impact, for papers by Jonathan H. Esensten Breakdown of academic impact, for papers by Mauro Congia Breakdown of academic impact, for papers by J. S. Lanchbury Breakdown of academic impact, for papers by J A Hansen Breakdown of academic impact, for papers by Mari Malkki Breakdown of academic impact, for papers by Gisela Orozco Breakdown of academic impact, for papers by Yojiro Arinobu Breakdown of academic impact, for papers by Tie Zheng Hou Breakdown of academic impact, for papers by Eric T. Elwood
Rankless by CCL
2026